Evidence map›Paper›PMID 22797184›Full record

ArticleJournal of the American Society of Nephrology : JASN2012

Dying cells and extracellular histones in AKI: beyond a NET effect?

Diane L Rosin, Mark D Okusa

Abstract readEditorialComment
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. The effect of palmitic acid on inflammatory response in macrophages: an overview of molecular mechanisms.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Sepsis and ARDS: The Dark Side of Histones.Mediators of inflammation · 2015
    Review
  11. Extracellular histones in tissue injury and inflammation.Journal of molecular medicine (Berlin, Germany) · 2014
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Diane L Rosin
Mark D Okusa

Funding

Sphingolipids in Acute Kidney Injury and Disease ProgressionR01DK085259 · NIDDK · UNIVERSITY OF VIRGINIA · PI OKUSA, MARK DOUGLAS · 2010 to 2023
$5.0M
Leukocyte Trafficking in Acute Renal FailureR01DK062324 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI OKUSA, MARK DOUGLAS · 2003 to 2016
$4.4M
Naturally Occurring IgM Anti-Leucocyte Autoantibodies Protect Against Renal IRIR01DK083406 · NIDDK · UNIVERSITY OF VIRGINIA · PI LOBO, PETER, OKUSA, MARK DOUGLAS · 2010 to 2014
$2.1M
Nanotherapeutics for acute kidney injuryR21DK093841 · NIDDK · UNIVERSITY OF VIRGINIA · PI KLIBANOV, ALEXANDER L, OKUSA, MARK DOUGLAS · 2012 to 2013
$425k
NIDDK NIH HHS R01 DK062324NIDDK NIH HHS R01 DK083406NIDDK NIH HHS R01 DK085259NIDDK NIH HHS R21 DK093841
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acute Kidney InjuryAnimalsHistonesMyeloid Differentiation Factor 88Toll-Like Receptor 2Toll-Like Receptor 4HistonesMyd88 protein, mouseMyeloid Differentiation Factor 88Tlr2 protein, mouseTlr4 protein, mouseToll-Like Receptor 2Toll-Like Receptor 4

Identifiers

PMID22797184
PMCPMC3402294

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.